Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Endocrine 2NET 1Gynecologic 1

Conditions

Carcinoma, Neuroendocrine 8Neuroendocrine Tumors 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Small Cell 2Carcinoma, Non-Small-Cell Lung 2Somatostatinoma 1Neuroendocrine Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

pembrolizumab 2Etoposide 2Cisplatin 2veliparib 1taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Podophyllotoxin 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1Nivolumab 1Molecular Diagnostic Techniques 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Drug Therapy 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Etoposide × Endocrine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡